<DOC>
	<DOCNO>NCT00562809</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Irbesartan 150/12.5 mg 300/25 mg patient hypertension control monotherapy .</brief_summary>
	<brief_title>The Efficacy Safety Irbesartan 150/12.5 mg 300/25 mg Patients With Mild Hypertension</brief_title>
	<detailed_description>The primary secondary endpoint apply sub-groups defined age , race , diabetes , metabolic syndrome prior HTN therapy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>The patient must hypertension uncontrolled SBP monotherapy . Patients read , sign receive copy inform consent prior study procedure Note : Female patient must postmenopausal one year , surgically sterilize , use medically accept method contraception ( intrauterine device , oral contraceptive , barrier method spermicide ) must agree use effective method contraception throughout study . Any history secondary hypertension History hypertensive encephalopathy , stroke , transient ischemic attack ( TIA ) within past 12 month History myocardial infarction , percutaneous transluminal coronary revascularization , coronary artery bypass graft , and/or unstable angina pectoris within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>